MDGL vs. PROSY
MDGL (Madrigal Pharmaceuticals, Inc.) and PROSY (Prosus N.V.) are both stocks. MDGL operates in Biotechnology (Healthcare), while PROSY operates in Internet Content & Information (Communication Services). Over the past 5 years, MDGL returned 34.82%/yr vs -0.56%/yr for PROSY. At a 0.18 correlation, their price movements are largely independent.
Performance
MDGL vs. PROSY - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, MDGL achieves a -17.44% return, which is significantly higher than PROSY's -26.62% return.
MDGL
- 1D
- 1.37%
- 1M
- -10.95%
- YTD
- -17.44%
- 6M
- -15.87%
- 1Y
- 62.66%
- 3Y*
- 21.44%
- 5Y*
- 34.82%
- 10Y*
- 46.09%
PROSY
- 1D
- -2.58%
- 1M
- -0.11%
- YTD
- -26.62%
- 6M
- -27.15%
- 1Y
- -15.15%
- 3Y*
- 10.69%
- 5Y*
- -0.56%
- 10Y*
- —
MDGL vs. PROSY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
MDGL Madrigal Pharmaceuticals, Inc. | -17.44% | 88.72% | 33.36% | -20.28% | 242.52% | -23.77% | 22.02% | -9.63% |
PROSY Prosus N.V. | -26.62% | 55.67% | 33.80% | -5.32% | -17.15% | -23.28% | 45.77% | -9.97% |
Correlation
The correlation between MDGL and PROSY is 0.11, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.11 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.13 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.18 |
Correlation (All Time) Calculated using the full available price history since Sep 13, 2019 | 0.18 |
Fundamentals
MDGL:
$13.96B
PROSY:
$101.26B
MDGL:
-$12.87
PROSY:
$1.91
MDGL:
10.21
PROSY:
7.94
MDGL:
25.68
PROSY:
1.83
MDGL:
$1.13B
PROSY:
$12.76B
MDGL:
$1.05B
PROSY:
$5.31B
MDGL:
-$287.63M
PROSY:
$10.72B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
MDGL vs. PROSY — Risk / Return Rank
MDGL
PROSY
MDGL vs. PROSY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Madrigal Pharmaceuticals, Inc. (MDGL) and Prosus N.V. (PROSY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| MDGL | PROSY | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.88 | ||
| Sortino ratioReturn per unit of downside risk | +2.79 | ||
| Omega ratioGain probability vs. loss probability | 1.26 | 0.93 | +0.33 |
| Calmar ratioReturn relative to maximum drawdown | 2.11 | -0.44 | +2.56 |
| Martin ratioReturn relative to average drawdown | 4.63 | -0.81 | +5.44 |
Loading charts...
Drawdowns
MDGL vs. PROSY - Drawdown Comparison
The maximum MDGL drawdown since its inception was -98.40%, which is greater than PROSY's maximum drawdown of -69.36%. Use the drawdown chart below to compare losses from any high point for MDGL and PROSY.
Loading charts...
Drawdown Indicators
| MDGL | PROSY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.40% | -69.36% | -29.04% |
Max Drawdown (1Y)Largest decline over 1 year | -29.36% | -39.09% | +9.73% |
Max Drawdown (3Y)Largest decline over 3 years | -52.88% | -39.09% | -13.79% |
Max Drawdown (5Y)Largest decline over 5 years | -61.41% | -60.96% | -0.45% |
Max Drawdown (10Y)Largest decline over 10 years | -82.19% | — | — |
Current DrawdownCurrent decline from peak | -20.25% | -37.79% | +17.54% |
Average DrawdownAverage peak-to-trough decline | -58.52% | -30.01% | -28.51% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 13.38% | 21.26% | -7.88% |
Volatility
MDGL vs. PROSY - Volatility Comparison
Madrigal Pharmaceuticals, Inc. (MDGL) and Prosus N.V. (PROSY) have volatilities of 13.71% and 13.50%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| MDGL | PROSY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 13.71% | 13.50% | +0.21% |
Volatility (6M)Calculated over the trailing 6-month period | 31.76% | 27.41% | +4.35% |
Volatility (1Y)Calculated over the trailing 1-year period | 45.97% | 32.46% | +13.51% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 133.37% | 43.10% | +90.27% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 117.49% | 41.64% | +75.85% |
Dividends
MDGL vs. PROSY - Dividend Comparison
Neither MDGL nor PROSY has paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
MDGL Madrigal Pharmaceuticals, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
PROSY Prosus N.V. | 0.00% | 0.00% | 0.28% | 0.25% | 0.20% | 0.20% | 0.12% |
Financials
MDGL vs. PROSY - Financials Comparison
This section allows you to compare key financial metrics between Madrigal Pharmaceuticals, Inc. and Prosus N.V.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
MDGL and PROSY have a correlation of 0.11, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
MDGL has higher volatility (13.71%) compared to PROSY (13.50%). In terms of maximum drawdown, MDGL dropped -98.40% vs PROSY's -69.36%.
MDGL currently has the higher Sharpe Ratio (1.35 vs -0.53), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for MDGL and PROSY
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer